Abstract 840P
Background
This study aimed to obtain a deeper understanding of the molecular mechanisms underlying extranodal NK/T-cell lymphoma, nasal type (ENKTCL) by conducting Next-Generation Sequencing (NGS) of patients with ENKTCL.
Methods
This study included patients with ENKTCL who had complete tissue NGS results from two prior prospective studies. Group 1 comprised early-stage patients, while advanced-stage or relapsed patients were classified into Group 2. R language was used to visualize the mutation data.
Results
40 out of 98 patients with ENKTCL from two prospective clinical trials were included. Group 1 comprised 67.5% (n=27) of the patients, while group 2 accounted for 32.5% (n=13). Mutations in KLRC2 (29.6%), CIITA (25.9%), KLRC1 (25.9%), ITK (18.5%) were exclusively observed in group 1, with KLRC2 mutations occurring significantly more frequently in group 1 than group 2 (P = 0.037). KMT2D and TP53 exhibited the highest mutation rates and displayed different amino acid alterations in the two groups. The top KEGG pathway enriched by mutated genes was non-small cell lung cancer in group 1, and hepatitis B pathway in group 2. Patients with JAK3 wild-type exhibited remarkably improved PFS and OS rates than those with JAK3 mutations (P = 0.003, P = 0.033). Improved OS was also observed in patients with BCOR wild-type, although no significantly difference was found in PFS (P = 0.049, P = 0.172). Patients with PD-L1-positive expression had a significantly longer OS compared to those with PD-L1-negative expression (P = 0.037). Patients with PD-L1 expression < 50% were more likely to have BCOR mutations (41.7% vs. 0%, P = 0.012) and JAK3 gene mutations (33.3% vs. 0%, P = 0.033) than those with PD-L1 expression ≥ 50%.
Conclusions
The present study has, for the first time, explored disparities in mutation rates, mutation sites, and associated pathways among patients with early-stage versus advanced-stage/relapsed ENKTCL. JAK3 mutations, BCOR mutations, and PD-L1-negative expression were associated with poor prognosis of ENKTCL. Patients with PD-L1 expression < 50% were more likely to have BCOR mutations and JAK3 mutations than those with PD-L1 expression ≥50%.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18